C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026)
C4 Therapeutics' (CCCC) quarterly EBITDA Margin came in at 451.64% in Q1 2026, down 4871.0% year-on-year from 9.47% in Q1 2025, and down 114.96% quarter-over-quarter from 210.1% in Q4 2025.
C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' EBITDA Margin history runs 8 years deep, the most recent figure standing at 451.64% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 4871.0% year-over-year to 451.64% in Q1 2026; TTM through Mar 2026 was 326.56%, a 3358.0% decrease from a year earlier, with the FY2025 full-year figure at 320.53%, up 1561.0% from the prior year.
- EBITDA Margin retreated to 451.64% in Q1 2026 per CCCC's latest filing, from 210.1% in the prior quarter.
- Across five years, EBITDA Margin topped out at 178.59% in Q2 2024 and bottomed at 1410.21% in Q2 2023.
- The 5-year median for EBITDA Margin is 440.99% (2025), against an average of 598.03%.
- Across the five-year window, EBITDA Margin sank 126575 bps in 2022 and surged 123162 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 1341.73% in 2022, then gained by 14 bps to 1147.72% in 2023, then jumped by 37 bps to 728.39% in 2024, then surged by 71 bps to 210.1% in 2025, then tumbled by 115 bps to 451.64% in 2026.
- Per Business Quant, the three latest CCCC EBITDA Margin figures stand at 451.64% (Q1 2026), 210.1% (Q4 2025), and 306.43% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -451.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -451.64% |
| Dec 31, 2025 | -210.10% |
| Sep 30, 2025 | -306.43% |
| Jun 30, 2025 | -440.99% |
| Mar 31, 2025 | -402.93% |
| Dec 31, 2024 | -728.39% |
| Sep 30, 2024 | -183.86% |
| Jun 30, 2024 | -178.59% |
| Mar 31, 2024 | -1,060.18% |
| Dec 31, 2023 | -1,147.72% |
| Sep 30, 2023 | -251.16% |
| Jun 30, 2023 | -1,410.21% |
| Mar 31, 2023 | -963.77% |
| Dec 31, 2022 | -1,341.73% |
| Sep 30, 2022 | -481.02% |
| Jun 30, 2022 | -197.95% |
| Mar 31, 2022 | -409.84% |
| Dec 31, 2021 | -75.98% |
| Sep 30, 2021 | -285.34% |
| Jun 30, 2021 | -226.11% |